REFRACTORY SOLID TUMOR
Clinical trials for REFRACTORY SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY SOLID TUMOR trials appear
Sign up with your email to follow new studies for REFRACTORY SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: SGT-53 drug trial launches
Disease control TerminatedThis early-stage study tests a new drug called SGT-53, given alone or with chemotherapy, in children and young adults (ages 1-21) with solid tumors that have come back or not responded to treatment. The main goals are to find safe doses and understand side effects. The study is c…
Matched conditions: REFRACTORY SOLID TUMOR
Phase: PHASE1 • Sponsor: SynerGene Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Matched conditions: REFRACTORY SOLID TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC